Our proprietary pipeline of drug candidates is built on deep molecular modeling and screening processes, combined with an extensive understanding of matrix pathobiology, immunology, and oncology. Peptides represent viable and validated leads for drug discovery, ultimately producing extremely potent and selective drugs.
Building on renowned expertise in oncology as well as in developing personalized medicine approaches, our technological approach and proprietary portfolio consist in selectively targeting the tumor microenvironment. Our commitment is to offer therapeutic solutions for solid tumors that are refractory to available treatments (high rate of relapse and/or lack of targeted therapies), including orphan tumor pathologies with high unmet medical needs.
Our drug discovery platform gathers translational know-how from deep in silico molecular modeling and exhaustive screening/selection procedure to animal validation. Scientific R&D team possesses renowned expertise in matricellular proteins and receptor biology in the purpose of translating cutting-edge science into innovative treatments. Thus, integrative knowledge at Apmonia Therapeutics is a powerful driver for the development of highly differentiated drug candidates.
Apmonia Therapeutics’ peptide-based technology named AP-01 (or TAX2 peptide) acts as an orthosteric selective antagonist for thrombospondin-1 (TSP-1) binding to CD47 membrane receptor. This original approach represents a new class of immune microenvironment modulator, while overcoming the limitations of other CD47 blocking approaches (i.e., cytopenia, hemagglutination and limited therapeutic window). Thanks to its unique and differentiated mode of action, we believe AP-01 to be invaluable to leverage the full anti-cancer potential of other therapeutic modalities through combination strategies in a broad range of tumors.
We are developing the first-ever selective antagonist of TSP-1/CD47 signaling
